Metsera Reports Q1 2025 Financial Results and Pipeline Progress

Summary

On May 12, 2025, Metsera, Inc. reported financial results for the first quarter of 2025, highlighting continued progress in its clinical pipeline for obesity and metabolic diseases. The company announced a cash position of $588 million, with research and development expenses increasing to $57.2 million due to product development costs. General and administrative expenses also rose to $8.6 million. Net loss for the quarter was $76.6 million. Metsera also provided updates on its pipeline, including the VESPER Phase 2b trials for MET-097i and ongoing Phase 1 trials for MET-233i. Additionally, the company announced organizational updates, including the appointment of Jon P. Stonehouse as a director and Matthew Lang as Chief Legal Officer.